75 results about "Membrane antigen" patented technology

The present disclosure relates to a method of treating prostate specific membrane antigen (PSMA) positive progressive metastatic castration resistant prostate cancer (mCRPC) by administering a therapeutically effective amount of a PSMA binding radioligand therapy (RLT) agent, preferably [177Lu] Lu-PSMA-617 (lutetium (177Lu) vevovortitide Tailaracetam), to a taxane primarily treated patient whose disease progresses after receiving a second generation ARPI.

The present disclosure relates to pharmaceutical compositions comprising [61Cu]Cu-NODAGA-PSMA I&T or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a prostate-specific membrane antigen (PSMA)-expressing tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.

The present disclosure relates to the synthesis of prostate-specific membrane antigen (PSMA) ligands useful in the treatment of diseases such as cancer. In particular, the present disclosure relates to methods for synthesizing PSMA ligands having a glutamic acid-urea-lysine (GUL) moiety and a chelator that may include a radiometal.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

To provide a method of synthesizing 2-(3{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid ([18F]DCFPyL), which is a radiotracer for prostate-specific membrane antigen (PSMA) PET imaging for prostate cancer.SOLUTION: A synthesis method comprises the following steps: (i) radiofluorinating a DCFPyL precursor comprising ester moiety-protecting groups to form a radiofluorinated DCPFPyL precursor; (ii) deprotecting the ester moiety-protecting groups of the radiofluorinated DCPFPyL precursor of the step (i) with phosphoric acid to form [18F]DCFPyL in a reaction mixture; and (iii) purifying the [18F]DCFPyL from the reaction mixture of the step (ii) to provide [18F]DCFPyL.SELECTED DRAWING: Figure 5

The present invention relates to small molecules having high affinity and specificity to prostrate-specific membrane antigen (PSMA) and methods of using them for therapeutic and diagnostic purposes.

Disclosed herein are isolated polypeptide and polypeptide complex compositions that comprise a prostate-specific membrane antigen (PSMA) binding domain that is linked to a peptide that impairs binding of the PSMA binding domain to PSMA.

This invention provides a combination for use in treating cancers that express prostate-specific membrane antigen (PSMA). [Solution] A combination comprising a PD-1 inhibitor, a CTLA-4 inhibitor, and a radiolabeled compound of formula Ia for use in treating PSMA-expressing cancer in the subject. JPEG2026049728000042.jpg45132 The aforementioned combination comprises one or more further anticancer agents, wherein the further anticancer agents are selected from octreotide, lanreotide, vapreotide, pasireotide, satreotide, everolimus, temozolomide, telotristat, sunitinib, sulfatinib, ribociclib, entinostat, and pazopanib.

The present invention discloses a complex comprising (a) a compound, which is CA007 *, CA008 *, or CA009 *, or a pharmaceutically acceptable salt thereof, and (b) a radionuclide, which is selected from the group consisting of 203Pb and 212Pb. Also disclosed is the use of said complexes in the manufacture of a medicament for the treatment of cancers expressing prostate specific membrane antigen (PSMA). (CA007 *) (CA008 *) (CA009 *)

Imaging and radiotherapeutic agents targeting fibroblast-activation protein-α (FAP-α) and / or prostate-specific membrane antigen (PSMA) and their use in imaging and treating FAP-α and / or PSMA-related diseases and disorders are disclosed.

A treatment for patients having cancer expressing Prostate Cancer Specific Membrane Antigen (PSMA) is disclosed. Said treatment involves the use of an 225Ac-radioconjugate, in particular 225Ac-PSMA-I&T. A dosage regimen that entails more frequent administration of the 225Ac-radioconjugate at lower dose level may be employed. This involves the use of a dosage of 50-75 kBq / kg of body weight on a dosing schedule of every 4-6 weeks. A flat dosing may also be employed where the dose does not depend on the body weight of the subject. Such dosing improve the benefit / risk profile with fewer adverse events and less discontinuations, dosing interruptions and reductions in dose. Of particular importance is a reduction in salivary gland toxicity and xerostomia.

A prostate-specific membrane antigen (PSMA)-targeting ligand compound and a chelate thereof and use thereof are provided. The PSMA-targeting ligand compound has a structure as shown in formula I, where R1, R2 and R4 are each independently selected from the group consisting of H and optionally substituted linear or branched C1-C5 alkyl; R3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl; X is a sulfur atom or an oxygen atom; Y is selected from the group consisting of a chemical bond and —NH—(CH2)m-, where m is an integer selected from 0-18; and Z is a radioactive metal ion chelating group.

A method for imaging inflammation associated with inflammatory bowel disease (IBD) has been disclosed, which involves administering an imaging agent targeting prostate-specific membrane antigen (PSMA) to a subject and acquiring images.

Provided herein are, inter alia, methods of treating prostate cancer in a subject by administering to the subject a combination comprising i) a chimeric polypeptide targeting PSMA and CD3, and ii) an androgen receptor antagonist.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human prostate specific membrane antigen (PSMA) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody with the complementarity determining region sequence provided by the invention can specifically recognize PSMA expressed by cells and tissues, has good affinity in combination with the PSMA, has high recognition sensitivity, can effectively resist the interference of complex non-target protein components in the cells / tissues, has no specific combination with non-target antigens, is suitable for immunological detection of the PSMA, and has good application prospects. The kit is especially suitable for western blot detection and immunohistochemical methods, and can reduce the occurrence rate of false positive and false negative results and improve the accuracy of immunodiagnosis.

The present application relates to the technical field of medicine, in particular to a functional nanomaterial based on choline phosphate-cell membrane interaction and application thereof.The present application modifies manganese mineralized black phosphorus nanomaterial by bio-inspired polymer pGluCP adsorption, which retains the excellent biocompatibility and photothermal performance of BP, and at the same time, pGluCP enhances the 'chassis' effect of the material, captures tumor-related antigens, and can simultaneously capture water-soluble antigens and water-insoluble membrane antigens and form pathogen-like micro-nanoparticles, which is helpful for antigen delivery and APC presentation, and provides a feasible tool for capturing non-water-soluble membrane antigens, which is a major challenge.MnBP and pGluCP synergistically act, and can realize the personalized conversion of autologous tumors to vaccine production and delivery.

Disclosed herein are modified HIV envelope immunogens, engineered nanoparticle vaccines comprising modified HIV envelope immunogens and methods of use thereof for HIV vaccines.

The invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, in particular to an amino adipic acid-urea derivative containing L-proline and application of the amino adipic acid-urea derivative. The radioactive preparation obtained by labeling the amino-containing adipic acid-urea derivative with radionuclide has high uptake in tumors, meanwhile, the uptake in kidneys is effectively reduced, and the radioactive preparation is specifically combined with prostate specific membrane antigens and can be used as a novel tumor radioactive drug with popularization and application values for prostate cancer diagnosis.

The present invention relates to a method for the detection and diagnosis of cancer associated with overexpression of prostate specific membrane antigen (PSMA) by administering a 64Cu-labeled sarcophagine compound Sar-bis PSMA in a dose of from about 100 MBq to about 300 MBq, and PET imaging of a patient, and a method for the detection and diagnosis of cancer associated with overexpression of prostate specific membrane antigen (PSMA) by administering a 64Cu-labeled sarcophagine compound Sar-bis PSMA in a dose of from about 100 MBq to about 300 MBq. The method allows for higher resolution images even at cancer sites with lower PSMA density, such as secondary lesions.

To provide prostate-specific membrane antigen (PSMA) ligands, and in particular, alternative multimodal PSMA ligands suitable for use as diagnostics and / or therapeutics.SOLUTION: The present disclosure provides PSMA ligands having: a glutamate-urea-lysine (GUL) moiety; a radioisotope; and a chelating agent that can comprise a radiometal.SELECTED DRAWING: None

The invention discloses a method for overcoming tumor immune desert-type drug resistance by using a nano-carrier delivery vaccine. The method comprises the following steps: realizing targeted immune activation and microenvironment remodeling by constructing a three-stage structure collaborative delivery platform; the system comprises core-shell lipid nanoparticles (LNP) constructed based on a liposome self-assembly technology, mesoporous silica nanoparticles (MSNs) are adopted as a slow release module, and a manganese dioxide (MnO2) nano-cluster is anchored by a surface modified amino column [6] arene-lactose pyridine host-guest complex through a pi-pi accumulation effect; according to the present invention, through the dual targeting modification, the tumor cell membrane camouflage (retaining EGFR, CD44 and other membrane antigens) and the ApoA1 mimic peptide (22A peptide) synergistically act, the enrichment amount of the nanometer vaccine in the tumor tissue is 5.2 times of the normal liver tissue, and the problems that the traditional vaccine difficultly penetrates through the compact matrix of the immune desert type tumor and the lymph node activation efficiency is low are solved.

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of prostrate-specific membrane antigen (PSMA). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PSMA.

The present disclosure relates to antigen-binding domains which bind the antigen prostate-specific membrane antigen (PSMA) and to chimeric antigen receptors (CARs) which comprise such antigen binding domains.

The present invention relates to a polyplex comprising a linear conjugate of LPEI and PEG. The LPEI and PEG fragments of the linear conjugate are preferably linked by a [3+2] cycloaddition between azide and alkene or alkyne to generate 1,2,3 triazole or 4,5-dihydro-1H-[1,2,3]triazole. The linear conjugate is further conjugated to a targeting fragment that can bind to prostate-specific membrane antigen (PSMA) to enable selective interaction with specific cell types. The conjugate can form a polyplex with a therapeutic agent, such as a nucleic acid, to deliver the therapeutic agent to cells.

PSMA targeted metal chelate nanodrugs, methods of making these nanodrugs and methods of using them for radiodiagnosis and radiotherapy are provided.

Conjugates of the formula T-L-A wherein T is a ligand targeting prostate specific membrane antigen (PSMA), L is a linker, and A is a radiosensitizer; a pharmaceutical composition comprising the conjugate and a pharmaceutically acceptable carrier; and methods of treating prostate cancer or metastases thereof in a patient using radiotherapy. A conjugate of formula T-L-A can be administered prior to or after administration of a conjugate of formula T-L-X, wherein X is or comprises a radiotherapy or (radiation) imaging agent. Conjugates of formula T-L-(X) A, pharmaceutical compositions comprising the same, and methods of use are also disclosed.

The invention discloses a tumor holoantigen nano vaccine as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The nano vaccine comprises a composite liposome, a nucleic acid TLR agonist adjuvant, a tumor cell membrane antigen and a tumor cell soluble antigen. The membrane antigen is embedded into the lipid bilayer, and the soluble antigen and the adjuvant are wrapped in the inner cavity of the lipid to form the nanoparticles with accurate structures. The preparation method comprises the following steps: splitting a tumor cell separation membrane antigen and a soluble antigen; mixing the membrane antigen and lipid to form a lipid phase, and mixing the soluble antigen and an adjuvant to form a water phase; finally, the two phases are self-assembled into the nano vaccine through a micro-fluidic chip. The two antigens are synergistically combined at the nanoscale, the problems that a single antigen is weak in immunogenicity and incomplete in coverage are solved, the synergic anti-tumor effect far better than that of a single antigen vaccine is shown in an animal model, the preparation process is universal and controllable, and an efficient platform is provided for individualized tumor immunotherapy.

This invention relates to the field of optical imaging. More specifically, it relates to fluorescent probes capable of effectively targeting prostate-specific membrane antigen (PSMA) and comprising heptamethrin dye having near-infrared (NIR) emission. The invention also relates to methods for preparing these compounds, pharmaceutical compositions and kits for introducing these compounds, and methods for using them as optical diagnostic agents in the imaging or treatment of diseases, particularly prostate cancer.

To provide a prostate-specific membrane antigen (PSMA) ligand.SOLUTION: The present disclosure provides a PSMA ligand having a glutamic acid-urea-lysin (GUL) part, and a chelate agent capable of including radioactive metal. The present disclosure also provides use of a compound in diagnostic imaging and a compound in medical treatments for prostate cancer.SELECTED DRAWING: None